Treatment 2.0: Catalyzing the next phase of treatment, care and support

Current Opinion in HIV and AIDS

Volumn 8, Issue 1, 2013, Pages 4-11

  Duncombe, Chris ^a   Ball, Andrew ^b   Passarelli, Carlos ^c   Hirnschall, Gottfried ^b  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNAIDS   (Switzerland)

Author keywords

antiretroviral therapy; cost effectiveness; HIV; Treatment 2.0

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL;

CD4+ T LYMPHOCYTE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; UNITED NATIONS; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84871926406     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835ba7ff     Document Type: Review

References (42)

1. Abuja Declaration on HIV/AIDS, tuberculosis and other related infectious diseases 2001. Available from: http://www.un.org/ga/aids/pdf/abuja-declar ation.pdf. [Accessed 12 July 2012]
2. Africa Public Health. Info and Africa Health HaSDIS. 2012 Multi year Health Financing Trends Analysis and 2012 Health Financing Scorecard. 2012 http://www.who.int/pmnch/media/news/2012/2012-health-financing-scorecard. pdf. [Accessed 12 July 2012].
3. WHO. The Abuja Declaration: Ten Years On. 2011 http://www.who.int/ healthsystems/publications/Abuja10.pdf. [Accessed 12 July 2012].
4. OECD. Development: Aid to developing countries falls because of global recession. 2012 http://www.oecd.org/dac/aidstatistics/developmentaidto developingcountriesfallsbecauseofglobalrecession.htm [Accessed 10 July 2012].
5. OECD. Outlook on aid survey on donors' forward spending plans 2012-2015. 2012 http://www.oecd.org/dataoecd/45/25/50056866.pdf. [Accessed 10 July 2012].
6. UNAIDS. Together we will end AIDS. 2012http://www.unaids.org/en/media/ unaids/contentassets/documents/epidemiology/2012/20120718-together wewillendaids-en.pdf. [Accessed 29 July 2012].
7. WHO. HIV Operational Plan 2012-2013: WHO's support to implement the Global Health Sector Strategy on HIV/AIDS. 2012http://whqlibdoc. who.int/publications/2012/9789241503709-eng.pdf. [Accessed 17 July 2012]
8. WHO. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector progress towards Universal Access. Progress report 2011. http://www. who.int/hiv/pub/progress-report2011/hiv-full-report-2011.pdf. [Accessed 17 July 2012]
9. UNAIDS. Political Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS. http://www.unaids.org/en/media/unaids/contentas sets/documents/document/2011/06/20110610-un-a-res-65-277-en.pdf. [Accessed 17 July 2012].
10. WHO. The strategic use of antiretrovirals to help end the HIV epidemic. 2012 www.who.int/hiv/pub/strategic-use. [Accessed 16 July 2012]
11. WHO. WHO Global health sector strategy on HIV/AIDS 2011-2015. 2011; http://www.who.int/hiv/pub/hiv-str ategy/en/index.html. [Accessed 16 July 2012]
12. UNAIDS. UNAIDS 2011-2015 Strategy: Getting to Zero. 2010 http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/ 2010/jc2034-unaids-str ategy-en.pdf. [Accessed 10 July 2012]
13. WHO. The Treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. 2011 http://whqlibdoc.who.int/publications/2011/ 9789241501934-eng.pdf. [Accessed 17 July 2012].
14. Sidibe M. Antiretrovirals for prevention: realizing the potential. closing commentary by the executive director of UNAIDS. Curr HIV Res 2011; 9:470-472.
15. Crawford KW, Ripin DH, Levin AD. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost efficient delivery in resourcelimited settings: a consensus statement. Lancet Infect Dis 2012; 12:550-560.
16. WHO. Short-Term Priorities for Antiretroviral Drug Optimization Meeting Report. 2011 http://whqlibdoc.who.int/publications/2011/9789241501941-eng.pdf. [Accessed 15 July 2012].
17. WHO. Strategic Use of Antiretrovirals for the Treatment and Prevention of HIV Infection; Report of a WHO technical consultation 2011 http://www.who.int/ hiv/pub/meetingreports/consultation-20111116/en/index.html. [Accessed 15 July 2012]
18. WHO. Technical update on treatment optimization. Use of efavirenz during pregnancy: a public health perspective June 2012. 2012 http://apps.who.int/iris/ bitstream/10665/70920/1/9789241503792-eng.pdf. [Accessed 16 July 2012].
19. WHO. Technical update on treatment optimization: Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. 2012 http://apps.who.int/iris/bitstream/10665/ 70936/1/9789241503815-eng.pdf. [Accessed 17 July 2012].
20. Medecines Sans Frontiè res. Untangling the Web Of Antiretroviral Price Reductions14th Edition July 2011. 2011 http://apps.who.int/medicine docs/documents/s18716en/s18716en.pdf. [Accessed 17 July 2012].
21. Initiative CHA. Antiretroviral (ARV) Ceiling Price List. 2012 http://www. clintonhealthaccess.org/files/CHAI-ARV-Ceiling-Price-List-May-2012.pdf. [Accessed 17 July 2012].
22. WHO. Technical update on treatment optimization: Use of tenofovir in HIVinfected children and adolescents: a public health perspective. 2012 http://apps.who.int/iris/bitstream/10665/70944/1/9789241503822-eng.pdf. [Accessed 17 July 2012].
23. UNITAID. HIV/AIDS diagnostic technology landscape. 2nd edition 2012; http://www.unitaid.eu/images/marketdynamics/publications/unitaid-md-technical- report-diagnostics-landscape-web.pdf. [Accessed 18 July 2012]
24. Van Rooyen H. High Testing Uptake and Linkages to HIV Treatment through Home-based HIV Counseling and Testing and Facilitated Referral: KwaZulu-Natal, South Africa [abstract]. In: 12th conference on retroviruses and opportunistic infections; Seattle 2012.
25. Molesworth AM, Ndhlovu R, Banda E, et al. High accuracy of home-based community rapid HIV testing in rural Malawi. J Acquir Immune Defic Syndr 2010; 55:625-630; Epub 2011/09/22.
26. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011; 378:1572-1579.
27. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
28. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resourcelimited setting. Trop Med Int Health 2012; 17:1152-1155.
29. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, de Wit TF, Hill AM, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26:1663-1672.
30. WHO. Antiretroviral therapy for HIV infection in adults and adolescents; Recommendations for a public health approach 2010 revision. 2010http:// whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf. [Accessed 20 July 2012]
31. Foundation for Innovative New Diagnostics. http://www.finddiagnostics. org/media/press/110203.html. [Accessed 20 July 2012].
32. Rottinghaus EK, Ugbena R, Diallo K, et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis 2012; 54:1187-1195.
33. UNAIDS. Inaugural Global Scientific Strategy Towards an HIV Cure launched ahead of the XIX International AIDS Conference in Washington DC. 2012 http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/ 2012/july/20120719prhivcure/. [Accessed 29 July 2012].
34. UNAIDS, UNCTAD, WHO, UNDP. Using TRIPS flexibilities to improve access to HIV treatment: Policy brief. 2006 http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/JC2049-PolicyBrief-TRIPS-en.pdf. [Accessed 19 July 2102].
35. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056.
36. Meta-analysis of Linkage to Care from HIV Diagnosis to Start of ART: Sub-Saharan Africa 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA March 5-8 2012. Poster abstract #1143.
37. Burtle D, Welfare W, Elden S, et al. Introduction and evaluation of a 'pre-ART care' service in Swaziland: an operational research study. BMJ open 2012; 2:e000195.
38. WHO. Retention in HIV programmes: defining the challenges and identifying solutions. http://www.who.int/hiv/pub/meetingreports/retention-programmes/en/ [Accessed 24 July 2012]
39. Duc Duong Bui FM, Thi Nhan Do, Masaya Kato, et al. Treatment 2.0 Pilot in Vietnam: early progress and challenges. World J AIDS 2012; 2(2).
40. Organization TPAH. Antiretroviral Treatment in the Spotlight: 2012 A Public Health Analysis in Latin America and the Caribbean. 2012 http://new. paho.org/hq/index.php?option1/4;com-docman&task1/4;doc-view&gid1/ 4;17512 &Itemid1/4;. [Accessed 24 July 2012]
41. Orsi F, d'Almeida C. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries. Curr Opin HIV AIDS 2010; 5:237-241.
42. UNAIDS. AIDS Dependency Crisis: Sourcing African Solutions. 2012 http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublica tion/2012/JC2286-Sourcing-African-Solutions-en.pdf. [Accessed 14 July 2012]